Currently, several large-scale intervention trials are underway to determine if B vitamin supplements (folic acid, B12, B6), which effectively lower blood homocysteine levels, reduce the incidence of vascular disease (Table 3). If proven effective, such supplements would be an inexpensive and relatively
Table 3 Intervention trials to determine the effect of B vitamin supplements on homocysteine and the risk of vascular disease
Location Start date
Cambridge Heart Antioxidant Study 2 UK 1998
Heart Outcomes Prevention Evaluation 2 Canada 1999 (HOPE-2)
Norwegian Multi-Center B-Vitamin Norway 1998
Intervention Study (NORVIT) Prevention with a Combined Inhibitor and Australia 2000 Folate in Coronary Heart Disease (PACIFIC)
Study of Effectiveness of Additional UK 1999
Reductions in Cholesterol and Homocysteine (SEARCH) Vitamins in Stroke Prevention (VISP) USA 1998
Vitamins to Prevent Stroke (VITATOPS) Australia 1999 Western Norway B-Vitamin Intervention Norway 1999 Trial (WENBIT)
Women's Antioxidant and Cardiovascular USA 1998 Disease Study (WACS)
innocuous means by which the risk of vascular disease may be reduced. However, it must be recognized that if these trials are successful, they will not serve as definitive proof that homocysteine is a vascular toxin. It may be the case that one or more of the B vitamins influences vascular disease risk through separate mechanisms. For example, several studies have shown that low B6 status has an association with vascular disease independent of homo-cysteine. The uncertain relationship between hyperhomocysteinemia, B vitamins, and vascular disease is summarized in Figure 2. If homocysteine is not a vascular toxin, it may still serve as a marker of both vascular disease and as an indicator of the efficacy of B vitamin supplementation.
B vitamin deficiencies
Was this article helpful?